Systemic reactions with aeroallergen cluster immunotherapy in a clinical practice

Area of Science:

• Allergy and Immunology
• Clinical Medicine
• Pharmacology

Background:

• Subcutaneous allergen-specific immunotherapy is effective for immunoglobulin E-mediated diseases.
• Low patient adherence to traditional immunotherapy stems from treatment inconvenience.
• Cluster immunotherapy presents a more convenient alternative, but concerns exist regarding systemic reaction rates during accelerated buildup.

Purpose of the Study:

• To evaluate the safety profile of cluster immunotherapy.
• To identify specific risk factors associated with systemic reactions during the cluster immunotherapy buildup phase.

Main Methods:

• A retrospective observational study was conducted.
• Data were collected from 441 patients undergoing cluster immunotherapy between May 2008 and October 2010.
• Systemic reactions were graded using the World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System.

Main Results:

• 10.9% of patients (48/441) experienced systemic reactions during cluster immunotherapy.
• The majority of reactions were mild (grade 1 and 2).
• Risk factors identified include female sex, asthma diagnosis, age 21-40, and specific allergen inclusion.

Conclusions:

• Cluster immunotherapy enables faster achievement of maintenance doses and potentially quicker symptom relief.
• The accelerated buildup phase in cluster immunotherapy is associated with an increased risk of systemic reactions.
• Understanding and identifying risk factors are crucial for enhancing the safety of cluster immunotherapy protocols.